Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 4/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.31 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209608 | 1.00 | MAPT (0.35) | MAPTKDM4EALDH1A1HTTCYP2D6 | |
| SCHEMBL79263 | 1.00 | MAPT (0.35) | MAPTKDM4EALDH1A1HTTCYP2D6 | |
| SCHEMBL487416 | 1.00 | MAPT (0.35) | MAPTKDM4EALDH1A1HTTCYP2D6 | |
| SCHEMBL77864 | 0.89 | CTSK (0.37) | CYP2D6MTNR1AMTNR1BALOX5APFEN1 | |
| SCHEMBL20981028 | 0.88 | MAPT (0.34) | MAPTKDM4EALDH1A1HTTDPP4 | |
| SCHEMBL78318 | 0.88 | MAPT (0.36) | MAPTCYP2D6DPP4MTNR1AMTNR1B | |
| SCHEMBL8337923 | 0.85 | MAPT (0.33) | MAPTKDM4EALDH1A1HTT | |
| SCHEMBL20827204 | 0.83 | MAPT (0.36) | MAPTKDM4EALDH1A1HTTCYP2D6 | |
| SCHEMBL20826999 | 0.82 | MAPT (0.40) | MAPTKDM4EALDH1A1HTTCASP3 | |
| SCHEMBL23268871 | 0.82 | CYP2D6 (0.36) | MAPTKDM4EALDH1A1HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000026198-A1 | N-SUBSTITUTED (3,6-DIHYDRO)-2H-1,2-OXAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MGLUR1 ANTAGONISTS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-05-11 | — | — | WO | claimed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-8362043-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| CN-1842521-B | Caspase inhibitors containing isoxazoline ring | LG LIFE SCIENCES LTD | 2012-09-05 | — | — | CN | disclosed |
| EP-2412707-A2 | 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1833794-B1 | 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7960415-B2 | Caspase inhibitors and uses thereof | Vertex Pharmaceutical Incoporated (US) | 2011-06-14 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923433-B2 | Activity-based probes and methods of their preparation and use | ACTIVX BIOSCIENCES, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| WO-2010120880-A1 | TREATMENT OF LIVER DISEASES WITH A CASPASE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2008056897-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | ACTIVX BIOSCIENCES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20060160862-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
| EP-1631549-A2 | 3-[2-(3-AMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1583726-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | Activx Biosciences, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004106304-A2 | 3 - [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-YL) - ACETYLAMINO] - 4- OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242494-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-02 | — | — | US | disclosed |
| WO-2004033397-A2 | ACTIVITY-BASED PROBES, AND METHODS OF THEIR PREPARATION AND USE | ACTIVX BIOSCIENCES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2002076968-A1 | MALONATES AS INHIBITORS OF THE ICE/CED-6 FAMILY OF CYSTEINE PROTEASES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| WO-2000026198-A1 | N-SUBSTITUTED (3,6-DIHYDRO)-2H-1,2-OXAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE MGLUR1 ANTAGONISTS | ELI LILLY AND COMPANY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | DNPEP, CTRL, ARSA | MAPT 2754/4885KDM4E 4087/4885ALDH1A1 565/4885 |
| US-20040242494-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | MAPT 3085/4885KDM4E 1324/4885ALDH1A1 1350/4885 |
| US-20060160862-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | MAPT 2777/4885KDM4E 1305/4885ALDH1A1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.